Glaxo shares lower as Grassley asks for FDA Paxil review

LONDON (MarketWatch) -- GlaxoSmithKline (GSK)


UK:GSK 1,061.50, -12.50, -1.2%) shares slipped in early London trade as Sen. Charles Grassley, the senior Republican on the Senate Finance Committee, called for the Food and Drug Administration to review its Paxil depression drug. He cited a U.K. investigation that the company held back data on the suicide risk from taking the drug. "I am asking the FDA to take a look at the same information that was examined in the U.K. And I am asking the FDA if we need to change any laws here in the United States," he said

Any politicians with balls as big as Sen Grassley here in the UK?

Stand up and be counted.

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON